Company Overview and News

0
Stock With Momentum: Bioalpha Holdings Bhd

2018-08-08 theedgemarkets
Bioalpha Holdings Bhd (-ve) TRADING of the shares in Bioalpha Holdings Bhd (fundamental: 2.25/3, valuation: 1.40/3) triggered our momentum algorithm yesterday for the third time this year.
0179 BSMAF 1818

0
Stock With Momentum: Bioalpha Holdings Bhd

2018-07-31 theedgemarkets
Bioalpha Holdings Bhd (+ve) TRADING of shares in Bioalpha Holdings Bhd (fundamental: 2.25/3, valuation: 1.4/3) triggered our momentum algorithm yesterday for the first time this year. The company saw 4.25 million shares traded, exceeding the counter’s 200-day average of 1.76 million. The stock closed unchanged at 25 sen, leaving it with a market capitalisation of RM206.55 million. Bioalpha Holdings was last traded at 1.
0179

0
MTDC will continue to invest in Bioalpha

2018-07-24 theedgemarkets
DUNGUN (July 24): The Malaysian Technology Development Corporation (MTDC) will continue to invest in local health supplement manufacturer, Bioalpha Holdings Bhd (Bioalpha), after seeing the company successfully penetrate local and Asian markets.
0179

0
Bioalpha eyes to produce 2,000 tonnes of herbs from new herbal park in Terengganu

2018-07-22 theedgemarkets
DUNGUN (July 22): Health supplement and beauty products manufacturer Bioalpha Holdings Bhd targets to produce 2,000 tonnes of herbs from its new Pasir Raja Herbal Park, a Herbal Integrated Cluster Development (HICD) project, located here in Terengganu, by 2020.
0179

Related Articles

REPH: Recro Pharma Analysis and Research Report

2018-08-20 - Asif

Overview Recro Pharma is a specialty pharmaceutical company that operates through two business divisions: an Acute Care division and a revenue-generating CDMO division. Each of these divisions are deemed to be reportable segments for financial reporting purposes. The company's Acute Care segment is primarily focused on developing and commercializing innovative products for hospital and related acute care settings. The company's lead product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor. IV meloxicam has successfully completed three Phase III clinical trials for the management of moderate to severe pain, consisting of two pivotal efficacy trials and a large double-blind Phase III safety trial, as well as other safety studies. Overall, the total new drug application, or NDA, program included over 1,400 patients. In late July 2017, the company submitted a NDA to the U.S. Food and Drug Administration, or FDA, for IV meloxicam...

ACHN: Achillion Pharmaceuticals Analysis and Research Report

2018-08-20 - Asif

Overview Achillion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on advancing its oral factor D inhibitors into late-stage development and commercialization. Each of the drug candidates in its oral factor D portfolio was discovered in its laboratories and is wholly owned by it. Achillion Pharmaceuticals is focusing its drug development activities on alternative pathway-mediated, rare diseases where there are no approved therapies or where existing therapies are inadequate for patients. To advance its investigational drugs into phase III and commercialization, the company plan to work closely with key stakeholders including patients, payors, regulators and healthcare professionals. The company's first-generation factor D inhibitor, ACH-4471, has demonstrated preliminary clinical proof-of-concept in patients with C3 glomerulopathy, or C3G, a disease affecting the kidney, and paroxysmal nocturnal hemoglobinuria, or PNH, a blood disorder, and has advanced...

BTE: Baytex Energy Trust Analysis and Research Report

2018-08-20 - Asif

General Baytex Energy Corp. was incorporated on October 22, 2010 pursuant to the provisions of the ABCA. Baytex is the successor to the business of Baytex Energy Trust, which was transitioned to Baytex on December 31, 2010. Inter-Corporate Relationships The following table provides the name, the percentage of voting securities owned by it and the jurisdiction of incorporation, continuance, formation or organization of its material subsidiaries either, direct and indirect, as at the date hereof. ||Percentage of voting securities (directly or indirectly)|Jurisdiction of Incorporation/Formation| | ------------ | ------------: | :------------: | |Baytex Energy Ltd.|100%|Alberta| |Baytex Energy USA, Inc.|100%|Delaware| |Baytex Energy Partnership|100%|Alberta| Organizational Structure The following simplified diagram shows the inter-corporate relationships among it and its material subsidiaries as of the date hereof. <img src="https://www.sec.gov/A...